Chemotherapy-induced nausea and vomiting (chemotherapyinduced emesis) is a common treatment-related side effect that has a detrimental effect on the quality of life of patients with cancer and may lead to dose reductions in or discontinuation of chemotherapy. The development of new antiemetic agents has dramatically changed the landscape of chemotherapy-induced emesis. In the 1970s, prolonged h...

Over the past 2 decades, substantial advances have been made in the management of chemotherapy-induced nausea and vomiting (CINV). This is primarily because of a deeper understanding of the molecular and physiologic pathways critical to CINV. The discovery of the 5-hydroxytryptamine type 3 (5-HT3) receptor and the subsequent development of 5-HT3 receptor antagonists (RAs) in the early 1990s rep...

antiemetics 5-Hydroxytryptamine type 3 receptor (5HT3) (serotonin) antagonists, corticosteroids and aprepitant are usually given once daily. However, for delayed emesis corticosteroids are given two times daily. Dopamine antagonists are given three or four times daily. For routine use oral doses are recommended [I, A]. Palonosetron is only available as an i.v. formulation. Substances of the sam...

BACKGROUND Oncology providers frequently underestimate the incidence of chemotherapy-induced nausea and vomiting (CINV), and patients often are reluctant to report symptoms. Inadequate patient-provider communication is a significant barrier to optimal management of this debilitating toxicity. METHODS The author reviews relevant published data and methods to optimize the clinical care of patie...

Chemotherapy-induced nausea and vomiting (CINV) remains a challenge in cancer care. Improved understanding of CINV pathophysiology has triggered the development of new antiemetic therapeutic options, such as selective neurokinin-1 (NK1) receptor antagonists (RAs), which effectively prevent CINV when added to a standard antiemetic regimen (serotonin-3 RA and dexamethasone). Aprepitant and its wa...

Chemotherapy-induced nausea and vomiting (CINV) is one of the most common symptoms feared by patients, but may be prevented or lessened with appropriate medications. Several antiemetic options exist to manage CINV. Corticosteroids, serotonin receptor antagonists, and neurokinin receptor antagonists are the classes most commonly used in the prevention of CINV. There are many alternative drug cla...

Chemotherapy-induced nausea and vomiting (CINV) is a concern for many cancer patients. It can have an enormous impact on quality of life. CINV occurring in the first 24 hours after treatment is considered acute, and CINV occurring on days 2 through 5 after treatment is considered delayed. Anticipatory nausea and depression can also occur when patients are reminded of their chemotherapy treatmen...